| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
93,430,000 |
| Market
Cap: |
9.47(B) |
| Last
Volume: |
1,926,795 |
Avg
Vol: |
847,074 |
| 52
Week Range: |
$87.54 - $153.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 224 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 4 |
|
|
|
|
|
| |
|
Company Profile Neurocrine Biosciences is applying its capabilities into neuroscience to develop medicines for neurology, neuroendocrinology and neuropsychiatry-related disorders and diseases. Co.'s commercially available medicines include INGREZZA®, which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 mg, 60 mg and 80 mg capsules); and ONGENTYS®, which is a once-daily, peripherally acting Catechol-O-methyltransferase inhibitor utilized to prolong the duration of effect of levodopa, the primary treatment option for Parkinson's disease patients, during periods of the day where the effects of levodopa wear off and motor symptoms worsen.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
207,103 |
275,797 |
453,738 |
1,303,254 |
| Total Sell Value |
$29,454,303 |
$39,131,074 |
$64,349,086 |
$174,500,333 |
| Total People Sold |
11 |
11 |
16 |
17 |
| Total Sell Transactions |
32 |
36 |
61 |
150 |
| End Date |
2025-01-19 |
2024-10-18 |
2024-04-19 |
2023-04-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roberts Eiry |
Chief Medical Officer |
• – – |
2025-02-14 |
4 |
AS |
$115.04 |
$57,521 |
D/D |
(500) |
35,640 |
|
-21% |
|
| Lippoldt Darin |
Chief Legal Officer |
• – – |
2025-02-13 |
4 |
AS |
$116.75 |
$254,992 |
D/D |
(2,184) |
43,405 |
|
-22% |
|
| Lippoldt Darin |
Chief Legal Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,100 |
44,491 |
|
- |
|
| Onyia Jude |
Chief Scientific Officer |
• – – |
2025-02-13 |
4 |
AS |
$116.75 |
$336,239 |
D/D |
(2,879) |
18,089 |
|
-22% |
|
| Onyia Jude |
Chief Scientific Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,407 |
19,536 |
|
- |
|
| Roberts Eiry |
Chief Medical Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,605 |
36,140 |
|
- |
|
| Roberts Eiry |
Chief Medical Officer |
• – – |
2025-02-13 |
4 |
AS |
$116.74 |
$200,742 |
D/D |
(1,718) |
34,768 |
|
-22% |
|
| Cooke Julie |
Chief Human Resources Officer |
• – – |
2025-02-13 |
4 |
AS |
$116.77 |
$181,129 |
D/D |
(1,551) |
20,190 |
|
-22% |
|
| Cooke Julie |
Chief Human Resources Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,910 |
20,945 |
|
- |
|
| Delaet Ingrid |
Chief Regulatory Officer |
• – – |
2025-02-13 |
4 |
AS |
$116.69 |
$171,674 |
D/D |
(1,471) |
4,730 |
|
-22% |
|
| Delaet Ingrid |
Chief Regulatory Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,759 |
5,485 |
|
- |
|
| Sherwin Stephen A |
Director |
– • – |
2025-02-13 |
4 |
AS |
$116.69 |
$1,613,923 |
D/D |
(13,831) |
10,673 |
|
-22% |
|
| Gano Kyle |
Chief Executive Officer |
• • – |
2025-02-13 |
4 |
AS |
$116.84 |
$298,908 |
D/D |
(2,558) |
139,907 |
|
-22% |
|
| Gano Kyle |
Chief Executive Officer |
• • – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,807 |
141,113 |
|
- |
|
| Gorman Kevin Charles |
Director |
– • – |
2025-02-13 |
4 |
AS |
$116.68 |
$681,914 |
D/D |
(5,844) |
524,209 |
|
-22% |
|
| Gorman Kevin Charles |
Director |
– • – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,979 |
527,221 |
|
- |
|
| Benevich Eric |
Chief Commercial Officer |
• – – |
2025-02-13 |
4 |
AS |
$116.71 |
$251,428 |
D/D |
(2,154) |
44,689 |
|
-22% |
|
| Benevich Eric |
Chief Commercial Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,044 |
45,745 |
|
- |
|
| Abernethy Matt |
Chief Financial Officer |
• – – |
2025-02-13 |
4 |
AS |
$116.85 |
$298,923 |
D/D |
(2,558) |
35,810 |
|
-22% |
|
| Abernethy Matt |
Chief Financial Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,807 |
37,016 |
|
- |
|
| Boyer David W. |
Chief Corp. Affairs Officer |
• – – |
2025-02-13 |
4 |
AS |
$116.69 |
$208,387 |
D/D |
(1,785) |
3,565 |
|
-22% |
|
| Boyer David W. |
Chief Corp. Affairs Officer |
• – – |
2025-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,352 |
4,395 |
|
- |
|
| Lippoldt Darin |
Chief Legal Officer |
• – – |
2025-02-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
190 |
41,489 |
|
- |
|
| Benevich Eric |
Chief Commercial Officer |
• – – |
2025-02-10 |
4 |
AS |
$118.31 |
$115,940 |
D/D |
(980) |
42,799 |
|
-24% |
|
| Roberts Eiry |
Chief Medical Officer |
• – – |
2025-02-10 |
4 |
AS |
$118.22 |
$115,853 |
D/D |
(980) |
33,253 |
|
-24% |
|
829 Records found
|
|
Page 1 of 34 |
|
|
1.28 (1.28%) 
